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Summary Background Docetaxel and prednisolone chemo-
therapy (DP) extends survival in metastatic castration resistant
prostate cancer (mCRPC). However, emergent clinical resis-
tance is almost inevitable. AKT pathway activation is highly
prevalent in mCRPC contributing to disease progression and
DP resistance. AZD5363 is a potent oral pan-AKT inhibitor
with pre-clinical data indicating activity in mCRPC and syner-
gy with docetaxel.Methods This phase I trial was to determine
an AZD5363 recommended phase II dose (RP2D) for combi-
nation with DP. Eligibility criteria included chemotherapy na-
ive mCRPC, PSA or radiographic disease progression and
ECOG performance status 0 or 1. Treatment comprised DP
(75mg/m2, IV, day 1 and 5mgBID, PO, day 1–21 respectively
for ten cycles) and AZD5363 to disease progression for all
patients.We utilised a 3 + 3 dose escalation design to determine
a maximum tolerated dose according to defined dose limiting
toxicity criteria assessed using CTCAE version 4.03. Planned
AZD5363 dose levels were 320 mg (DL1), 400 mg (DL2) and
480 mg (DL3), BID, PO, 4 days on/3 days off, from day 2 of
each cycle. Results 10 patients were treated. Dose limiting
toxicities affected 2 patients (grade 3 rash ≥5 days; grade 3
diarrhoea) in DL2. The commonest grade 3 or 4, AZD5363
related, symptomatic adverse events were rash and diarrhoea.
Hyperglycaemia affected all patients but was self-limiting.
PSA reduction to <50% at 12 weeks occurred in 7 patients.
Conclusions The RP2D for AZD5363 is 320 mg BID, 4 days
on/3 days off, in combination with full dose DP for mCRPC.
Keywords Castration resistant prostate cancer . Metastatic .
Docetaxel . AZD5363 . Phase I . AKT
Introduction
There are approximately 47,000 new cases and 11,000 deaths
from prostate cancer in the UK per year [1]. Docetaxel and
prednisolone chemotherapy (DP) extends survival and main-
tains quality of life in metastatic castration resistant prostate
cancer (mCRPC) [2, 3]. However, despite the advent of che-
motherapy utilisation earlier in the treatment pathway for hor-
mone sensitive disease, and the introduction of multiple other
life extending therapeutic options, advanced prostate cancer
remains incurable [4–12]. From the point of castrate resis-
tance, median survival is in the range of 2–3 years [4–6].
One contributory factor in these outcomes is the common
phenomenon of emergent therapeutic resistance either during,
or shortly following, the administration of DP for mCRPC.
For example, in a 755 patient phase III study evaluating sub-
sequent chemotherapy, three quarters of patients had
progressed during or within 3 months of completing DP [8].
A pressing unmet need, therefore, remains to develop
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therapeutic strategies to address clinical resistance to DP and
improve on current outcomes.
Serine/threonine protein kinase AKT (protein kinase B)
pathway activation is highly prevalent in prostate cancer. In
addition to the loss of PTEN function through deletion,
inactivating mutation, or reduced protein expression, the fre-
quency of pathway alteration rises substantially when
inactivating PHLPP and INPP4B alterations or activating
PI3K component (PIK3R1, PIK3R3, PIK3CA) and AKT iso-
form mutations are also included as potential causes of path-
way activation [13]. Data indicate that the rate of a potentially
activating pathway alteration rises to approaching 100% if
assessed within metastatic samples. Furthermore, in pre-
clinical models AKT pathway activation has been shown to
contribute to disease progression and therapeutic resistance to
DP [13–15].
AZD5363 is a potent oral pan-AKT inhibitor with activity
against AKT 1, 2 and 3 (IC50 < 10 nM). It also inhibits protein
kinase A (PKA) and the Rho associated protein kinases
(ROCK1 and 2). AZD5363 inhibits phosphorylation of
AKT substrates GSK3β and PRAS40 and the downstream
biomarker S6 in cell lines, including LNCaP prostate cancer
cells and rodent xenografts including from PC3 prostate can-
cer cells. Pre-clinical data support both single agent activity in
mCRPC and synergy with docetaxel [14, 16, 17]. In first in
human studies as a single agent, diarrhoea, hyperglycaemia,
nausea, and rash were the most common adverse events (AE)
[18, 19]. Exploratory data from these single agent trials is
consistent with relevant signalling inhibition based on pre-
and post-treatment tumour biopsies (increase in phospho-
AKT, reduction in phospho-GSK3β and phospho-PRAS40)
and clinical activity in patients with PIK3CA-mutant breast
cancer and in patients with tumour AKT1 (E17K) mutations
[18, 19].
The ProCAID phase I clinical trial was undertaken to es-
tablish a DP/AZD5363 combination to allow for subsequent
development in mCRPC and potentially also earlier phases of
the disease pathway.
Patients and methods
Patients
Eligible patients were 18 years or older with histologically or
cytologically proven mCRPC and an Eastern Cooperative
Oncology Group performance status of 0 or 1. All patients
had disease progression based on PSA and/or radiographic
criteria defined by the Response Evaluation Criteria in Solid
Tumors (RECIST, version 1.1) and the Prostate Cancer
Working Group 2 [20, 21]. Radiologically measurable and/
or evaluable disease was acceptable. Patients were required
to have a serum testosterone <1.7 nmol/L and ongoing
LHRH analogue or antagonist therapy was permitted to main-
tain a castrate state. Other therapies for prostate cancer, other
than ongoing bisphosphonates or denosumab, were
discontinued ≥4 weeks prior to commencing study treatment
and anti-androgen withdrawal response was excluded where
relevant. Haematological parameter requirements were:
haemoglobin ≥9 g/dL, platelets ≥100 × 109/L, neutrophils
≥1.5 × 109/L, bilirubin ≤ the institutional upper limit of normal
(ULN), alanine (ALT) and aspartate (AST) aminotransferase
≤1.5 x ULN and sodium and potassium within the normal
range for the treating institution. Patients were excluded if
they had received previous treatment with cytotoxic chemo-
therapy but were permitted the prior use of second generation
hormonal therapies e.g., abiraterone or enzalutamide. Other
exclusion criteria included prior malignancywith an estimated
≥30% chance of relapse within 2 years, previously identified
brain metastases, or spinal cord compression unless treated
with full functional recovery, prior radiotherapy to >30% of
bone marrow, another investigational agent within 30 days of
study medication, type I or II diabetes mellitus requiring either
insulin or oral hypoglycaemics for routine management, gas-
trointestinal conditions that might affect drug absorption, sig-
nificant cardiac disease within the last 6 months, a left ven-
tricular ejection fraction < the institutional lower limit of nor-
mal, a QTc interval of >480msec, or recent exposure to potent
inhibitors or inducers of CYP3A4 or substrates of CYP3A4
and CYP2D6. The complete eligibility criteria are listed in the
Supplementary Appendix.
Treatment
The treatment cycle is summarised in Fig. 1 and comprised
DP for up to 10 cycles of 21 days. All patients received doce-
taxel 75mg/m2 by one hour intravenous infusion on day 1 and
prednisolone 5 mg BID, orally, on days 1 to 21 of each cycle.
In addition, patients received AZD5363 which was continued
until either disease progression, the commencement of new
anti-prostate cancer systemic therapy or unacceptable toxicity.
Planned AZD5363 dose levels were 320 mg (dose level 1),
400 mg (dose level 2) and 480 mg (dose level 3), BID, orally,
given according to a 4 days on and 3 days off schedule which
commenced from cycle 1, day 2. Dexamethasone pre-
medication was recommended at 8 mg, orally, at 12, 3 and
1 h prior to each docetaxel infusion and anti-emetics were
given according to local institutional protocols. Body surface
area calculations and re-calculations due to changes in weight
and docetaxel dose banding (up to +/− 5%) were permitted in
accordance with local institutional practices.
Study design
We utilised a conventional 3 + 3 dose escalation phase I clin-
ical trial design. An evaluable patient was defined as one that
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completed cycle 1 and received at least 80% of the total cu-
mulative doses of AZD5363 and prednisolone, and the full
dose of docetaxel, with nomore than a 14-day delay in starting
cycle 2, or who had experienced a dose limiting toxicity
(DLT). AE data was recorded for all patients who commenced
study treatment.
The National Cancer Institute Common Toxicity Criteria
for Adverse Events version 4.03 (CTCAEv4.03, http://evs.
nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_
QuickReference_5x7.pdf) was used to characterise AEs.
DLTs were predefined and based on recorded AEs as: a
greater than 14 day delay in administration of docetaxel
for cycle 2 due to drug toxicity; grade 4 neutropenia
≥7 days duration; grade 3 or 4 neutropenia associated
with a temperature ≥ 38.5 °C; grade 3 or 4 neutropenia
associated with bacteriologically proven sepsis; any grade
4 thrombocytopenia; grade 3 thrombocytopenia associated
with non-traumatic bleeding (except where this could be
explained by therapeutic anticoagulation); ≥ grade 3
hyperglycaemia for more than 1 week despite optimal in-
tervention; grade 4 hyperglycaemia; AST or ALT >10 x
ULN where AZD5363 was considered the most likely
cause; AST or ALT >8 x ULN when combined with a
doubling of bilirubin from baseline and where AZD5363
was considered the most likely cause; QTc (Fridericia’s or
Bazett’s correction) interval > 500 msec or QTc increase
>60 msec from baseline on two ECGs at least 30 min apart
that could not be attributed to another cause; symptomatic
congestive cardiac failure (New York Heart Association
class III/IV) and a drop in LVEF that could not be attrib-
uted to another cause; a decrease in LVEF of ≥20% to a
level below the institutional lower limit of normal range;
clinically significant rash that despite optimal treatment
remained grade ≥ 3 for 5 days or longer and that could
not be attributed to another cause; grade ≥ 3 nausea,
vomiting or diarrhoea, despite optimal anti-emetic or anti-
diarrhoeal therapy and which could not be attributed to
another cause; any other grade ≥ 3 toxicity which in the
opinion of the investigator was clinically significant and
related to AZD5363. Designation of a DLT excluded iso-
lated laboratory changes of any grade (except as specified
above) without clinical sequelae or clinical significance.
Intra-patient dose escalation was not permitted. In addi-
tion to protocol defined DLTs, the protocol allowed for the
Safety Review Committee to consider other toxicities in-
cluding those emerging during subsequent treatment cycles
in prior patients in making recommendations. Dose esca-
lation was undertaken if none of 3, or 1 of 6, evaluable
patients experienced a DLT at the current dose level. If 2
or more patients experienced a DLT then the preceding
dose level was established as the maximum tolerated dose
(MTD). The recommended phase II dose (RP2D) was the
MTD or dose level three if this was tolerated.
The primary endpoint was the determination of an RP2D
for AZD5363, using a four days on/three days off administra-
tion schedule, in combination with full dose DP. Secondary
endpoints included safety and tolerability profiles using
CTCAEv4.03 and AZD5363 pharmacokinetics when com-
bined with DP. Results were summarised descriptively.
Trial conduct was consistent with Good Clinical
Practice guidelines and the Declaration of Helsinki and
following national ethics and regulatory approvals.
Informed consent was obtained from all individual par-
ticipants included in the study. The trial was coordinat-
ed by the Cancer Research UK Southampton Clinical
Trials Unit and sponsored by University Hospital
Southampton NHS Foundation Trust.
Results
Patients
Ten patients with a median age of 67.5 (range 56–72) were
recruited from two UK centres with 4 patients in dose level 1,
and 6 in dose level 2. Nine patients (90%) had bony metasta-
ses and 5 (50%) had visceral metastases. One patient in dose
level 1 was considered to be non-evaluable for DLT assess-
ment due to a compliance error, resulting frommisunderstand-
ing rather than treatment related AEs, in cycle 1 resulting in
only 54.2% of the cumulative AZD5363 dose being taken.
This patient subsequently tolerated treatment at full dose from
cycle 2 onwards. Patient characteristics are shown in Table 1.
Day
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
Docetaxel X
Dexamethasone X
AZD5363 X X X X X X X X X X X X
Prednisolone X X X X X X X X X X X X X X X X X X X X X
Fig. 1 Schematic representation of the days of dosing (blue crossed
boxes) for each of the indicated drugs at the following doses: docetaxel,
75 mg/m2 by one hour intravenous infusion on day 1; dexamethasone
8 mg orally, at 12, 3 and 1 h prior to each docetaxel infusion; AZD5363,
dosed according to dose level cohort, BID, orally, taken 4 days on/3 days
off, continuously from cycle 1 day 2; prednisolone, 5 mg BID orally days
1–21
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Dose escalation and safety
Amedian of 8.5 cycles (range 3–10) of DP and 4 cycles (range
1–13) of AZD5363 was administered. The actual number of
cycles administered for each patient is shown in Table 2. In
dose level 1, all 3 evaluable patients received an equal or
greater number of cycles of AZD5363 compared to DP. In
dose level 2 however, this was the case for only 2 of 6 patients.
The 4 other patients in dose level 2 received only 1 or 2 cycles
of AZD5363 whilst receiving between 3 and 10 cycles of
docetaxel. No DLTs were seen in dose level 1. Two patients
in dose level 2 experienced DLTs. These were due to grade 3
rash for ≥5 days and grade 3 diarrhoea despite optimal anti-
diarrhoeal therapy. The severity and number of AEs overall
and by dose level is shown in Table 3. Five patients in cycle 1,
and 8 (80%) across all cycles had at least one grade 3 or 4 AE.
Rates of specific AEs, occurring in at least one patient, are
shown for cycle 1 (Table 4) and across all cycles (Table 5).
Across all cycles, the most common grade 3 or 4 AEs
considered by the investigator to be related to AZD5363 were
maculopapular rash and diarrhoea (3 patients and 2 patients
respectively). In most cases of rash and diarrhoea, utilisation
of systemic anti-histamines and loperamide respectively
Table 1 Patient characteristics
Dose level 320 mg (n = 4) 400 mg
(n = 6)
All patients
(n = 10)
Age
Median, years
(range)
66.5 (56–68) 68 (62–72) 67.5 (56–72)
≥ 65 years, n (%) 3 (75%) 4 (67%) 7 (70%)
ECOG performance status, n (%)
0 3 (75%) 4 (67%) 7 (70%)
1 1 (25%) 2 (33%) 3 (30%)
Gleason score at diagnosis, n (%)*
≤ 6 0 0 0
7 2 (50%) 2 (33%) 4 (40%)
8–10 2 (50%) 3 (50%) 5 (50%)
Metastatic sites, n (%)
Bone only 2 (50%) 3 (50%) 5 (50%)
Visceral only 1 (25%) 0 1 (10%)
Visceral and bone 1 (25%) 3 (50%) 4 (40%)
Prior abiraterone or enzalutamide
n (%) 0 3 (50%) 3 (30%)
PSA, μg/L
Median, (range) 175 (76–320) 115 (0.7–620) 115 (0.7–620)
Haemoglobin, g/L
Median, (range) 136.5
(132–160)
133
(105–147)
134.5
(105–160)
Alkaline Phosphatase (U/L)
Median (range) 118 (74–524) 151.5
(76–720)
135 4–720)
Abbreviations ECOG Eastern Cooperative Oncology Group, PSA pros-
tate specific antigen
*Gleason score was not recorded for one patient (who had a confirmed
diagnosis of cancer from a prostate biopsy)
Table 2 Number of cycles of DP and AZD5363 receved for each
patient
Patient Dose
level
Number of
cycles of DP
administered
Number of
cycles of AZD5363
administered
051001 1 10 3
051002 1 7 7
051003 1 10 10
051004 1 10 13
051005 2 10 2
051006 2 6 1
028007 2 10 13
051008 2 5 5
051009 2 3 1
051010 2 4 2
Table 3 Adverse events (by CTCAE version 4.03) summary
Dose level 320 mg
(n = 4)
400 mg
(n = 6)
All patients
(n = 10)
Cycle 1
Number of AEs per patient
Median 7.5 11.5 9.5
Range 3–14 4–33 3–33
Worst CTCAE grade experienced, n (%)
1 – Mild 1 (25%) 2 (33%) 3 (30%)
2 – Moderate 2 (50%) 0 2 (20%)
3 – Severe 1 (25%) 3 (50%) 4 (40%)
4 – Life threatening 0 1 (17%) 1 (10%)
5 – Death 0 0 0
At least one grade ≥ 3
event
1 (25%) 4 (67%) 5 (50%)
All cycles
Number of AEs per patient
Median 23 23.5 23.5
Range 17–26 22–76 17–76
Worst CTCAE grade experienced, n (%)
1 – Mild 0 0 0
2 – Moderate 1 (25%) 1 (17%) 2 (20%)
3 – Severe 3 (75%) 4 (67%) 7 (70%)
4 – Life threatening 0 1 (17%) 1 (10%)
5 – Death 0 0 0
At least one grade ≥ 3
event
3 (75%) 5 (83%) 8 (80%)
Abbreviations: AE, adverse event; CTCAE, Common Toxicity Criteria
for Adverse Events
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allowed for successful management and to allow ongoing ad-
ministration of study medication. Febrile neutropenia oc-
curred in 2 (20%) of patients across all treatment cycles.
There were no treatment related deaths.
Transient hyperglycaemia is an expected AE for both
AZD5363 and corticosteroids. Dexamethasone was used
as chemotherapy pre-medication and prednisolone is
routinely administered with docetaxel for mCRPC [2].
We saw hyperglycaemia in every patient. The mean
random glucose on cycle 1 day 2 (first dose of
AZD5363) was 6.0 mmol/L pre-dose and then
8.7 mmol/L at 2 h, 9.5 mmol/L at 4 h, and 6.5 mmol/
L at 8 h post AZD5363 dose. Insulin and C-peptide
levels also rose and fell in parallel to these glucose
changes in all patients. Individual patient data are
shown in Fig. 2. No patient experienced symptomatic
complications as a result of hyperglycaemia or required
intervention to correct a high glucose level (an algo-
rithm, including criteria for metformin administration,
was provided within the trial protocol).
Pharmacokinetics
Pharmacokinetic analyses indicated that AZD5363 exposure
for patients receiving concomitant DP chemotherapy was in
keeping with that found in patients receiving mono-therapy in
the AZD5363 development programme.
Treatment efficacy
PSA reduction from baseline level to <50% (PSA50) at
12 weeks of treatment was seen in 7 (70%) of patients (Fig. 3).
Table 4 Adverse events (CTCAE version 4.03), regardless of causality, occurring during cycle 1 of treatment*
Dose level 320 mg (n = 4) 400 mg (n = 6) All patients (n = 10)
Grade ≥ 1 Grade ≥ 3 Grade ≥ 1 Grade ≥ 3 Grade ≥ 1 Grade ≥ 3
Diarrhoea 3 (75%) 0 5 (83%) 2 (33%) 8 (80%) 2 (20%)
Rash 2 (50%) 0 4 (67%) 3 (50%) 6 (60%) 3 (30%)
Neutropenia 0 0 2 (33%) 2 (33%) 2 (20%) 2 (20%)
Fever 0 0 2 (33%) 1 (17%) 2 (20%) 1 (10%)
Febrile neutropenia 0 0 1 (17%) 1 (17%) 1 (10%) 1 (10%)
Hypokalaemia 0 0 1 (17%) 1 (17%) 1 (10%) 1 (10%)
ALP increased 1 (25%) 1 (25%) 0 0 1 (10%) 1 (10%)
Abbreviations CTCAE Common Toxicity Criteria for Adverse Events, ALP alkaline phosphatase
*No grade 5 events occurred in any patient
Table 5 Adverse events (by CTCAE version 4.03), regardless of causality, occurring in all cycles of treatment
Dose level 320 mg (n = 4) 400 mg (n = 6) All patients (n = 10)
All grades Grade ≥ 3 All grades Grade ≥ 3 All grades Grade ≥ 3
Diarrhoea 3 (75%) 0 5 (83%) 2 (33%) 8 (80%) 2 (20%)
Rash 3 (75%) 0 4 (67%) 3 (50%) 7 (70%) 3 (30%)
Pruritus 3 (75%) 1 (25%) 1 (17%) 0 4 (40%) 1 (10%)
Neutropenia 0 0 3 (50%) 3 (50%) 3 (30%) 3 (30%)
Fever 0 0 3 (50%) 1 (17%) 3 (30%) 1 (10%)
Febrile neutropenia 0 0 2 (33%) 2 (33%) 2 (20%) 2 (20%)
Infection 1 (25%) 1 (25%) 1 (17%) 0 2 (20%) 1 (10%)
Thromboembolic event 0 0 1 (17%) 1 (17%) 1 (10%) 1 (10%)
Urinary Tract Infection 1 (25%) 1 (25%) 0 0 1 (10%) 1 (10%)
Hypokalaemia 0 0 1 (17%) 1 (17%) 1 (10%) 1 (10%)
Hyperkalaemia 0 0 1 (17%) 1 (17%) 1 (10%) 1 (10%)
ALP increased 1 (25%) 1 (25%) 0 0 1 (10%) 1 (10%)
Abbreviations CTCAE Common Toxicity Criteria for Adverse Events, ALP alkaline phosphatase
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Fig. 2 Individual patient data for
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indicated time points during cycle
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Discussion
We undertook a phase I, open-label, combination dose esca-
lation trial to determine an appropriate dose for AZD5363 to
be used in combination with conventional doses of DP che-
motherapy for use in mCRPC. The resulting RP2D for
AZD5363 in this combination is 320 mg, BID, PO, given
according to a 4 days on and 3 days off schedule and com-
mencing from cycle 1, day 2 based on pre-defined criteria for
dose limiting toxicity. In addition we found that the higher
AZD5363 dose level of 400 mg BID resulted in 4 of 6 patients
discontinuing AZD5363 within the first 2 cycles of treatment
despite being able to tolerate further DP cycles. This supports
the selection of the 320 mg BID dose level for this combina-
tion, which by comparison was tolerable at a level broadly
consistent with the use of DP alone in this setting over multi-
ple cycles [2, 3].
The most common AEs which were considered to be asso-
ciated with the addition of AZD5363 to chemotherapy were
diarrhoea, rash, neutropenia and hyperglycaemia in keeping
with the experience to date of single agent AZD5363 admin-
istration [18, 19]. Diarrhoea and rash responded in most pa-
tients to management with loperamide and systemic anti-
histamines with most patients able to continue therapy in the
face of these AEs. We did not see evidence of increased nau-
sea, at least above that experienced with DP, which has been
an AE in single agent studies.
Hyperglycaemia occurred in all patients who received
AZD5363 but was transient and self-limiting within 8 h of
the first AZD5363 dose. We had chosen a 4 days on 3 days
off schedule for dosing of AZD5363. This was one approach
under evaluation within single agent AZD5363 trials at the
point that our trial was designed. Our choice of this schedule
was driven, in part, to allow us to separate temporally the
administration of AZD5363 from the relatively high doses
of dexamethasone pre-medication administered prior to doce-
taxel in an attempt to reduce the potential for interaction to
drive hyperglycaemia. This strategy appears to have been suc-
cessful and despite the concurrent use of prednisolone at com-
paratively lower doses. Of note, our study excluded patients
with type I or II diabetes mellitus requiring either insulin or
oral hypoglycaemics for routine management which should be
borne in mind in the subsequent development of this
approach.
This study was not designed to evaluate the efficacy of this
combination at this stage of development. The PSA50 re-
sponse rate of 70% of patients, and the fact that we adminis-
tered a median of 8.5 cycles of chemotherapy is broadly con-
sistent with prior data from large randomised trials of DP in
this setting [2, 8]. However, we are unable to determine on this
current experience what additional benefit AZD5363 might
add to DP alone in this setting which will form the basis of
future development of this combination. On the basis of our
results, recruitment is currently ongoing to a placebo-
controlled randomised phase II trial in mCRPC to evaluate
the impact on progression free survival of the addition of
AZD5363 to DP compared to DP alone. Collection of tissue
samples, and blood sampling for circulating biomarkers will
allow us to undertake exploratory analyses within this latter
trial for patient subsets that might benefit based on activation
of the PI3K/AKT signalling pathway.
Our determination of a proposed RP2D at 320 mgBID on a
4 day on/3 day off schedule for combination with DP was
based on the treatment of 4 patients at this dose level, of which
3 were fully evaluable. Within a standalone trial this would
have required a dose level expansion cohort to confirm toler-
ability. Our approach instead has been to confirm tolerability
through direct progression to a placebo controlled,
randomised, phase II component of the trial which is currently
recruiting. Patients are randomised (1:1) to DP/AZD5363 or
DP/placebo. Following recruitment of the first 20 randomised
patients, a prospectively planned review by a fully indepen-
dent Data Monitoring and Ethics Committee (DMEC) has
considered toxicity and tolerability data to which the DMEC
were unblinded. On the basis of this review, the committee
have recommended ongoing recruitment. This approach to
undertaking a dose level expansion cohort was chosen to pro-
vide efficiencies in moving through the development of this
treatment approach such that these patients will also contrib-
ute to the subsequent phase II efficacy assessment based on a
primary endpoint of progression free survival.
AKT inhibition utilising AZD5363 is also being developed
in other combination approaches. Of note, RE-AKT is an on-
going multicentre, randomised, phase I/II trial in mCRPC,
evaluating a combination of AZD5363 with the androgen re-
ceptor antagonist enzalutamide (https://clinicaltrials.gov/ct2
/show/NCT02525068) [22]. In addition, analogous data for a
taxane combination has been reported in breast cancer for
AZD5363 plus paclitaxel, with the same 4 day on/3 day off
AZD5363 schedule [23]. Toxicities were broadly similar, as
Fig. 3 Percentage change from baseline of individual patient prostate
specific antigen (PSA) level after 12 weeks of therapy
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was the RP2D, although at a dose level higher, at 400 mgBID,
giving further reassurance that our RP2D of 320 mg BID is
likely to prove tolerable.
In conclusion, AZD5363 at a dose of 320 mg BID on a
4 day on/3 day off schedule is recommended for further eval-
uation in combination with full dose DP for mCRPC.
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